Walgreens Didn't Die of One Wound. It Died of Three It Saw Coming.

On March 6, 2025, Walgreens agreed to sell itself for $11.45 a share.⁶ For a company that traded near sixty-six dollars at its 2015 peak⁹ — itself a number that once seemed a floor, not a ceiling — that price is not a valuation, it is a coroner's report. A retail-focused private equity firm, Sycamore Partners, offered an eight-percent premium to a stock that had already lost most of its worth, and the board took it.⁶ The official framing is rescue: a patient turnaround taken private to heal away from the glare of quarterly earnings. The honest reading is liquidation at a clearance price, and the autopsy is not subtle about cause of death.

Walgreens did not die of one bad bet. It died of three — and the grim part is that management had the data to see each one coming. A pivot into primary care that bled cash, opioid liabilities measured in billions, and a core pharmacy whose margin was quietly hollowing out the whole time. Any one of them was survivable. Stacked, with each draining the cash needed to absorb the others, they compounded into a take-private at a price that confirmed the value was already gone.

Wound one: paying nearly $10 billion to lose money faster

The strategy on paper was elegant. Bolt doctors' offices onto drugstores: the patient sees the physician, fills the prescription on the way out, and the pharmacy that was bleeding to Amazon and mail-order¹¹ suddenly owns the whole visit. So Walgreens bought into VillageMD — $1 billion in 2020, then $5.2 billion in 2021 to take majority control, then another $3.5 billion in January 2023 to fund VillageMD's purchase of Summit Health.³ Nearly $10 billion deployed to put a doctor next to the pharmacist — $1 billion in 2020, $5.2 billion in 2021, and $3.5 billion more in early 2023 — and by that point the company proudly hit its target of 200 co-located clinics.³ The clinics were real. The economics were not. Primary care is a low-margin, capital-hungry, slow-to-mature business, and Walgreens was funding its expansion while its own balance sheet was already thinning. The bet that the visit would rescue the prescription assumed Walgreens could afford to lose money at the doctor's office long enough to win at the counter. It could not.

By August 2024, VillageMD had defaulted on its $2.25 billion secured term loan, and Walgreens began exploring a sale of the entire stake it had spent four years and ten-plus billion dollars assembling.⁸ The write-down landed in the FY2024 numbers like a falling building: the healthcare-services segment posted a $14.2 billion operating loss, against $1.7 billion a year earlier, dominated by a $12.7 billion goodwill impairment in U.S. Healthcare.⁸ The doctor's office that was supposed to save the pharmacy instead detonated inside it.

Wound two: the bill for every pill, arriving late

While the company was busy building clinics, the bill for an older business decision was coming due. In December 2022, a national opioid settlement with CVS and Walgreens together reached $10.7 billion, with Walgreens' share set at $5.7 billion paid out over fifteen years.⁴ Then in April 2025 — weeks after the Sycamore deal — the Justice Department added a separate federal settlement of up to $350 million, $300 million in base payments plus $50 million contingent on a sale or merger before 2032 — a condition met by the Sycamore transaction.⁵⁵ The federal case resolved allegations that Walgreens had illegally filled unlawful opioid prescriptions from August 2012 through March 2023 — a span of nearly eleven years.⁵

The popular telling lumps these into one giant number and gets it wrong twice over. They are two independent proceedings, and the $10.7 billion headline was for two companies, not one. But the strategic point survives the correction: the opioid liability was a multibillion-dollar drain spread across fifteen years of future cash flow, locked in at exactly the moment Walgreens most needed that cash to fund a turnaround. The timing is the dagger. A company with a healthy core can amortize a long-tail legal liability without flinching. A company already burning capital on a failing pivot cannot — every dollar promised to the settlement was a dollar not available to fix the store.

Wound three: a store that no longer paid its rent

The first two wounds get the headlines. The third is the one that made them fatal, because it removed the cushion. Walgreens' core was around 8,700 U.S. stores — and by its own admission roughly a quarter of them were unprofitable.⁷ That is the quiet number that explains everything else. A drugstore footprint that large is a bet on foot traffic and front-of-store margin, both of which had been eroding for years as PBM reimbursement rates squeezed pharmacy margins into negative territory¹⁰ and Amazon eroded the front-of-store sales that once subsidised them.¹¹ In October 2024 the company announced it would close about 1,200 stores over three years, 500 of them in fiscal 2025 alone.⁷ You do not shutter a seventh of your locations from a position of strength. You do it when the locations have become liabilities pretending to be assets.

Wasn't going private the smart, brave move?

The fair objection is that taking a struggling company private is exactly the right play — escape the quarterly treadmill, restructure away from the spotlight, fix the thing in peace. Sycamore is a retail specialist; perhaps it sees a path the public market couldn't price. There is something to this. A patient owner can close 1,200 stores and absorb a fifteen-year settlement without a stock chart screaming at every step. But look at the number. $11.45 a share is roughly an eight-percent premium to a stock that had already fallen most of the way from its peak.⁶ Including the company's roughly $9 billion of debt, the whole enterprise changed hands for close to $24 billion⁶ — a fraction of what the public market once valued it at, and itself a confession. A rescue preserves value. A take-private at this price does not preserve value; it confirms the value was already destroyed and hands the wreckage to whoever will carry off the salvageable parts. The bravery isn't in the buyer. It's in the board admitting the public-company chapter was over.

The FY2024 filing reads like a ledger of the fall: goodwill cut from $28.2 billion to $15.5 billion in a single year, a $14.1 billion operating loss, a loss of $10.01 per share.¹² None of it was bad luck. The clinics were bought with eyes open; the prescriptions were filled by the company's own pharmacists; the unprofitable stores were unprofitable for years before anyone closed them. Walgreens spent a decade making three defensible-sounding decisions that, taken together, left no cash to survive any of them. The $11.45 wasn't the cause of the collapse. It was the receipt.